Janus kinases to jakinibs : from basic insights to clinical practice

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/327839

Lähdeviite

Gadina , M , Le , M T , Schwartz , D M , Silvennoinen , O , Nakayamada , S , Yamaoka , K & O'Shea , J J 2019 , ' Janus kinases to jakinibs : from basic insights to clinical practice ' , Rheumatology , vol. 58 , pp. 4-16 . https://doi.org/10.1093/rheumatology/key432

Julkaisun nimi: Janus kinases to jakinibs : from basic insights to clinical practice
Tekijä: Gadina, Massimo; Le, Mimi T.; Schwartz, Daniella M.; Silvennoinen, Olli; Nakayamada, Shingo; Yamaoka, Kunihiro; O'Shea, John J.
Tekijän organisaatio: Institute of Biotechnology
University of Helsinki
Päiväys: 2019-02
Kieli: eng
Sivumäärä: 13
Kuuluu julkaisusarjaan: Rheumatology
ISSN: 1462-0324
DOI-tunniste: https://doi.org/10.1093/rheumatology/key432
URI: http://hdl.handle.net/10138/327839
Tiivistelmä: Cytokines are critical mediators of diverse immune and inflammatory diseases. Targeting cytokines and cytokine receptors with biologics has revolutionized the treatment of many of these diseases, but targeting intracellular signalling with Janus kinase (JAK) inhibitors (jakinibs) now represents a major new therapeutic advance. We are still in the first decade since these drugs were approved and there is still much to be learned about the mechanisms of action of these drugs and the practical use of these agents. Herein we will review cytokines that do, and just as importantly, do not signal by JAKs, as well as explain how this relates to both efficacy and side effects in various diseases. We will review new, next-generation selective jakinibs, as well as the prospects and challenges ahead in targeting JAKs.
Avainsanat: cytokines
signal transduction
Janus kinases
kinase inhibitors
autoimmunity
inflammation
MODIFYING ANTIRHEUMATIC DRUG
COMBINED IMMUNE-DEFICIENCY
SELECTIVE JAK-1 INHIBITOR
RHEUMATOID-ARTHRITIS
INADEQUATE RESPONSE
TYROSINE KINASE
PRIMARY MYELOFIBROSIS
TRANSCRIPTION FACTORS
VX-509 DECERNOTINIB
DISEASE-ACTIVITY
1182 Biochemistry, cell and molecular biology
3121 General medicine, internal medicine and other clinical medicine
Vertaisarvioitu: Kyllä
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: acceptedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
Gadina_et_al_Rh ... us_kinases_to_jakinibs.pdf 936.1KB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot